JP7386852B2 - ペプチド活性化剤 - Google Patents

ペプチド活性化剤 Download PDF

Info

Publication number
JP7386852B2
JP7386852B2 JP2021514457A JP2021514457A JP7386852B2 JP 7386852 B2 JP7386852 B2 JP 7386852B2 JP 2021514457 A JP2021514457 A JP 2021514457A JP 2021514457 A JP2021514457 A JP 2021514457A JP 7386852 B2 JP7386852 B2 JP 7386852B2
Authority
JP
Japan
Prior art keywords
cells
cell
lck
peptide
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514457A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019218016A5 (https=
JP2021523946A5 (https=
JP2021523946A (ja
Inventor
アグレス，マイケル，ヴァレンティン
Original Assignee
インテルク ペプチド セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901673A external-priority patent/AU2018901673A0/en
Application filed by インテルク ペプチド セラピューティクス リミテッド filed Critical インテルク ペプチド セラピューティクス リミテッド
Publication of JP2021523946A publication Critical patent/JP2021523946A/ja
Publication of JPWO2019218016A5 publication Critical patent/JPWO2019218016A5/ja
Publication of JP2021523946A5 publication Critical patent/JP2021523946A5/ja
Application granted granted Critical
Publication of JP7386852B2 publication Critical patent/JP7386852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021514457A 2018-05-15 2019-05-15 ペプチド活性化剤 Active JP7386852B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901673 2018-05-15
AU2018901673A AU2018901673A0 (en) 2018-05-15 Peptide Activating Agent
PCT/AU2019/050463 WO2019218016A1 (en) 2018-05-15 2019-05-15 Peptide activating agent

Publications (4)

Publication Number Publication Date
JP2021523946A JP2021523946A (ja) 2021-09-09
JPWO2019218016A5 JPWO2019218016A5 (https=) 2022-05-24
JP2021523946A5 JP2021523946A5 (https=) 2022-05-24
JP7386852B2 true JP7386852B2 (ja) 2023-11-27

Family

ID=68539135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514457A Active JP7386852B2 (ja) 2018-05-15 2019-05-15 ペプチド活性化剤

Country Status (8)

Country Link
US (2) US11912789B2 (https=)
EP (1) EP3794014A4 (https=)
JP (1) JP7386852B2 (https=)
KR (1) KR102918269B1 (https=)
CN (1) CN112399970B (https=)
AU (1) AU2019268412B2 (https=)
CA (1) CA3100074A1 (https=)
WO (1) WO2019218016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518187B (zh) * 2020-04-16 2022-05-10 中国农业科学院饲料研究所 抗菌肽dn6nh2及其应用
JP2024532850A (ja) * 2021-08-20 2024-09-10 インテルク ペプチド セラピューティクス リミテッド がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522094A (ja) 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
WO2009038026A1 (ja) 2007-09-18 2009-03-26 Kurume University Ｃｔｌ誘導剤組成物
JP2010535508A (ja) 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
JP2011520436A (ja) 2008-05-14 2011-07-21 イマティクス バイオテクノロジーズ ゲーエムベーハー サービビン由来の新規で強力なｍｈｃクラスｉｉペプチド
JP2012511583A (ja) 2008-12-10 2012-05-24 パーデュー・リサーチ・ファウンデーション 細胞透過性ペプチドを用いたキナーゼ阻害剤
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
JP2015510393A (ja) 2012-01-24 2015-04-09 インター・ケー・ピーティーワイ・リミテッド 癌治療用ペプチド剤
US20170327543A1 (en) 2010-09-08 2017-11-16 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
AU2005204275B2 (en) * 1999-06-28 2008-10-16 Inter-K Pty Limited A method of modulating integrin mediated cellular activity and agents useful for same
AU2007231835A1 (en) * 2000-12-22 2007-11-29 Inter-K Pty Limited Screening assay for an inhibitor of MAP kinase?integrin binding
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US20120277161A1 (en) * 2009-02-23 2012-11-01 Inter-K Pty Limited Inhibition of multiple cell activation pathways
US20110200560A1 (en) * 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN112368293A (zh) 2018-05-15 2021-02-12 英特肽治疗有限公司 活化剂

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007522094A (ja) 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
JP2010535508A (ja) 2007-08-07 2010-11-25 パデュー リサーチ ファンデイション キナーゼ阻害薬およびその使用
WO2009038026A1 (ja) 2007-09-18 2009-03-26 Kurume University Ｃｔｌ誘導剤組成物
JP2011520436A (ja) 2008-05-14 2011-07-21 イマティクス バイオテクノロジーズ ゲーエムベーハー サービビン由来の新規で強力なｍｈｃクラスｉｉペプチド
JP2012511583A (ja) 2008-12-10 2012-05-24 パーデュー・リサーチ・ファウンデーション 細胞透過性ペプチドを用いたキナーゼ阻害剤
JP2012518602A (ja) 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
US20170327543A1 (en) 2010-09-08 2017-11-16 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
WO2012174412A2 (en) 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
JP2015510393A (ja) 2012-01-24 2015-04-09 インター・ケー・ピーティーワイ・リミテッド 癌治療用ペプチド剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
British Journal of Dermatology，Vol.162, No.1，2009年，p.29-41

Also Published As

Publication number Publication date
AU2019268412A1 (en) 2020-12-03
EP3794014A4 (en) 2022-03-16
CN112399970A (zh) 2021-02-23
JP2021523946A (ja) 2021-09-09
WO2019218016A1 (en) 2019-11-21
CN112399970B (zh) 2025-12-12
KR102918269B1 (ko) 2026-01-28
CA3100074A1 (en) 2019-11-21
AU2019268412B2 (en) 2024-11-07
KR20210021984A (ko) 2021-03-02
EP3794014A1 (en) 2021-03-24
US20210214391A1 (en) 2021-07-15
US11912789B2 (en) 2024-02-27
US20250019397A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
US20260103488A1 (en) Activating agents
KR102806143B1 (ko) 유전자 발현을 위한 나노입자 및 이의 용도
US20250019397A1 (en) Peptide Activating Agent
JP7187486B2 (ja) Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
Geng et al. TLR5 ligand–secreting T cells reshape the tumor microenvironment and enhance antitumor activity
AU2017359333A1 (en) Compositions and methods of modulating anti-tumor immunity
US20200399392A1 (en) Inhibitors of pla2-g1b cofactors for treating cancer
US20240425560A1 (en) IL-18 Variants and Uses Thereof
US20220378890A1 (en) Immunogenic egfr peptide compositions and their use in the treatment of cancer
JP2025163127A (ja) 同種異系腫瘍細胞ワクチン
CA3137031A1 (en) Compositions and methods for treating t cell exhaustion
US11702632B2 (en) Ex vivo method of generating super regulatory T cells for the prevention of autoimmune disease
CN108144049A (zh) 泛素化途径相关因子在调控调节性t细胞功能中的应用
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
JP2022535045A (ja) 細胞間近接相互作用の検出および免疫療法用の腫瘍特異的抗原反応性ｔ細胞の単離のための化学酵素的方法
CA3184316C (fr) Complexe immunomodulateur et ses applications pour la therapie
US20230313140A1 (en) Method for preparing t cells for adoptive t cell therapy
Kujawa Development of small molecule immunomodulators of the human immune system for cancer therapy
Mohan The role of LKB1 spliceoforms in iTreg-Th17 plasticity and their interactions with PKCθ and SIRT1 downstream of IL-6 signaling
Park The Molecular Mechanism of RIPK1-Induced Cell Death And Its Impact On The Immune Response
WO2025247951A1 (en) Fyn kinase inhibitors, combinations and uses thereof
Gilmour Investigating the T cell Intrinsic Regulatory Role of VISTA in Anti-Tumor Immunity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231114

R150 Certificate of patent or registration of utility model

Ref document number: 7386852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150